Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
GLAXOSMITHKLINE NZ LIMITED,Mepolizumab,"Eosinophilic asthma, lowering minimum blood eosinophil count to 300 cells per microlitre",Mepolizumab (Nucala),Options for investment,Community and Hospital,Oncology Agents and Immunosuppressants
